Improved drug-screening tests of candidate anti-cancer drugs in patient-derived xenografts through use of numerous measures of tumor growth determined in multiple independent laboratories.
<h4>Background</h4>Researchers screen candidate anti-cancer drugs for their ability to inhibit tumor growth in patient-derived xenografts (PDXs). Typically, a single laboratory will use a single measure of tumor growth.<h4>Purpose</h4>An effective drug-screening test as one t...
Saved in:
| Main Authors: | Elizabeth Rosenzweig, David E Axelrod, Derek Gordon |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0324141 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improved drug-screening tests of candidate anti-cancer drugs in patient-derived xenografts through use of numerous measures of tumor growth determined in multiple independent laboratories
by: Elizabeth Rosenzweig, et al.
Published: (2025-01-01) -
Patient‐derived xenografts: Practical considerations for preclinical drug testing
by: Charles E. de Bock
Published: (2025-04-01) -
P24 | DEVELOPMENT OF HEAD AND NECK SQUAMOUS CELL CARCINOMA PATIENT-DERIVED XENOGRAFTS (PDXS) AND ORGANOIDS (PDXOS) FOR MORPHOLOGICAL ANALYSIS AND DRUG SCREENING
Published: (2025-08-01) -
Anti-cancer drug sensitivity testing and preclinical evaluation of the anti-cancer potential of WEE1 inhibitor in triple-negative breast cancer patient-derived organoids and xenograft models
by: Seungyeon Ryu, et al.
Published: (2025-06-01) -
Activity prediction of anti-cancer drug candidate ERα inhibitor
by: XIA Yulan, et al.
Published: (2022-09-01)